15 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Sep 21
Report of Foreign Private Issuer
6:02am
. The initiation of dosing in our Phase IIb trial represents an important step towards this goal. The study was already approved by several Ethics Committees
20-F/A
yhjvnqfxpnv
23 Jan 20
Annual report (foreign) (amended)
4:31pm
20-F
788v8ategar6xm6
31 Mar 15
Annual report (foreign)
12:00am
424B4
ti9ni bgf
31 Jul 14
Prospectus supplement with pricing info
12:00am
F-1/A
a62as57 3e9si3
8 Jul 14
Registration statement (foreign) (amended)
12:00am
- Prev
- 1
- Next